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Summary
 
The T cell receptor complex (TCR) 
 
z
 
 chain is constitutively tyrosine phosphorylated specifi-
cally at two of the six 
 
z
 
 immunoreceptor tyrosine-based activation motif (ITAM) tyrosine resi-
dues in resting peripheral T cells. Further phosphorylation of 
 
z
 
 is induced by both agonist and
antagonist ligands of the TCR, with agonists inducing complete phosphorylation of the 
 
z
 
ITAM tyrosines. After antagonist stimulation, 
 
z
 
 phosphorylation is incomplete and generates
discrete forms of partially phosphorylated ITAMs. Here, we mutate specific tyrosines in chi-
meric human CD8-
 
z
 
 molecules to reflect phosphorylation in resting T cells as well as phosphor-
ylation induced by agonist and antagonist ligands. We demonstrate that such partially phosphor-
ylated TCR-
 
z
 
 species can inhibit IL-2 production in T cell hybridomas and proliferation in T
cell clones. This reveals a previously unrecognized, inhibitory function of partially phosphory-
lated ITAMs. These findings support the concept that TCR antagonism can arise through
the generation of an inhibitory signal within the TCR complex and that constitutive 
 
z
 
 phos-
phorylation in resting T cells is an inhibitory signaling environment.
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T
 
he TCR of resting mature T cells is constitutively ty-
rosine phosphorylated within the TCR 
 
z
 
 chain, the
function of which has not been established. Phosphoryla-
tion of 
 
z
 
 occurs at the tyrosines of its three immunorecep-
tor tyrosine-based activation motifs (ITAMs; for immuno-
receptor-based activation motif with the consensus sequence
D/ExxYxxL/Ix
 
6–8
 
YxxL/I).
 
1
 
 ITAMs are necessary and suf-
ficient to mediate T cell activation, as has been unambigu-
ously revealed by the incorporation of isolated ITAMs into
chimeric proteins (1–3). All evidence gathered thus far in-
dicates that both tyrosines in ITAMs are required for func-
tional activity (4). Truncated or mutated ITAMs cannot me-
diate T cell activation (1, 2, 5–7); however, it has not been
assessed whether ITAMs that can only be partially phos-
phorylated could possibly inhibit T cell activation.
The TCR complex contains a total of ten ITAMs within
the CD3 
 
e
 
, 
 
g
 
, 
 
d
 
, and 
 
z
 
 chains. The presence of multiple
ITAMs is thought to amplify signals generated by the
TCR. Mice expressing 
 
z
 
 protein without functional
ITAMs can provide the necessary signals for T cell devel-
opment (8, 9), because other components of the TCR
complex can substitute for 
 
z
 
 ITAMs. The ITAMs of the 
 
z
 
chain are therefore not essential for T cell maturation.
However, when present, the multiple 
 
z
 
 ITAMs determine
the selection of specific T cells during both positive and
negative selection (10). Thus, the 
 
z
 
 chain plays an impor-
tant role in shaping the TCR repertoire.
We have recently examined the actual sites of phosphor-
ylation of the six tyrosines of 
 
z
 
 (11). We found that the six
tyrosines were not phosphorylated to an equal extent. In
resting T cells, only two of the six 
 
z
 
 ITAM tyrosines were
phosphorylated. Stimulation of the TCR with antagonist
ligands augmented the phosphorylation of these two 
 
z
 
 ty-
rosines. In addition, two other tyrosines were weakly phos-
phorylated. Antagonist ligands thus led to an accumulation
of partially but specifically phosphorylated 
 
z
 
 species. In
contrast, agonists induced complete phosphorylation of all
six 
 
z
 
 tyrosines in a specific order. Thus, the quality of 
 
z
 
 phos-
phorylation was different in resting and antagonist-stimu-
lated T cells versus fully activated T cells. This raised the
question of whether the different types of 
 
z
 
 phosphoryla-
tion have functional consequences for T cell activation. One
possibility is that 
 
z
 
 phosphorylation of resting or antago-
nist-stimulated T cells simply reflects a low level of activa-
tion below the threshold for inducing full T cell activation.
Alternatively, it is possible that this type of phosphorylation
actively inhibits T cell activation.
TCR antagonism occurs when T cells are simulta-
neously exposed to stimulatory and antagonist ligands (12–
16). The mechanism of TCR antagonism is unclear. One
 
1
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hypothesis is that the two different ligands compete for
binding to the TCR. Another hypothesis is that nonstimu-
latory ligands induce an inhibitory signal and therefore ac-
tively inhibit activation by the stimulatory TCR ligand.
Antagonist ligands can induce early intracellular signaling
events, with the phosphorylation of the CD3 
 
z
 
 chain being
the most prominent (17–20). However, signals downstream
of 
 
z
 
 phosphorylation are greatly diminished, including the
activation of Zap-70. The Zap-70 kinase is known to bind
to fully phosphorylated 
 
z
 
 ITAMs through its tandem Src
homology (SH)2 domains before its activation (21, 22). 
 
z
 
Phosphorylation induced by antagonist ligands with in-
completely phosphorylated ITAMs hence does not support
recruitment of Zap-70 and its subsequent activation.
For this report, we directly tested whether the distinct
phosphorylation of 
 
z
 
 in resting T cells induced by antago-
nist ligands has functional consequences for T cell activa-
tion. To this end, we mutated tyrosines of 
 
z
 
 ITAMs to re-
flect phosphorylation of resting T cells or phosphorylation
induced by antagonist or agonist ligands. Whereas partially
phosphorylated 
 
z
 
 species cannot induce T cell activation by
themselves, we found that their presence can inhibit TCR-
mediated T cell activation.
 
Materials and Methods
 
Cells and Antibodies.
 
The 3.L2 T cell clone and hybridoma
and their maintenance and specificity were previously described
(23, 24). The T cell hybridoma 3A9 was described in reference 25.
Cells from the murine B cell line CH27, or Hi7, an I-E
 
k
 
–trans-
fected fibroblast line, were used as APCs. Anti-human (h)CD8
 
a
 
antibodies were RPA-T8 (PharMingen) for FACS
 
®
 
 analysis and
OKT-8 (American Type Culture Collection [ATCC]) for cross-
linking. OKT-8 was purified from tissue culture supernatants us-
ing protein A. Rabbit anti–Zap-70 was the gift of A.C. Chan
(Washington University, St. Louis, MO). Anti-
 
z
 
 polyclonal anti-
serum 777 (11) and biotinylated 4G10 (Upstate Biotechnology
Inc.) were used for immunoblotting. Phoenix E cells were ob-
tained from ATCC with permission from G. Nolan (Stanford
University, Palo Alto, CA). T cell lines were established from
splenocytes from 2.102 TCR–transgenic mice bred to recombi-
nation activating gene (RAG)-1
 
2
 
/
 
2
 
 mice (26). For maintenance
of 2.102 cell lines, 2 
 
3 
 
10
 
5
 
 2.102 T cells were restimulated bi-
weekly with 5 
 
3 
 
10
 
6
 
 irradiated B6.AKR splenocytes, 1 
 
m
 
M pep-
tide Hb(64–76), and 33 U/ml IL-2. For subcloning of 2.102
lines, 2.5 
 
3 
 
10
 
5
 
 B6.AKR splenocytes, 1 
 
m
 
M Hb(64–76), and 33
U/ml IL-2 was incubated in round-bottomed wells.
 
Tissue Culture Assays.
 
Antagonist assays of T hybridoma lines
were performed as previously described (14) with Hi7 cells as
APCs. Proliferation of 2.102 lines was performed as follows: 5 
 
3
 
10
 
4
 
 CH27 cells were prepulsed with Hb(64–76), treated with mi-
tomycin C (Sigma Chemical Co.) for 2 h at 37
 
8
 
C, washed three
times, and then incubated with 3 
 
3 
 
10
 
4
 
 2.102 T cells. Thymidine
was added after 48 h.
 
Transfection and Retroviral Infection.
 
3.L2 and 3A9 cells were
transfected by electroporation and selected with Zeocin (Invitro-
gen Corp.). Phoenix E cells were transfected using CaCl
 
2
 
 for
production of high titer retroviral supernatants (27). 2.102 T cells
were infected with retroviral supernatants 3 d after activation (27).
 
Constructs.
 
The chimera between the extracellular and trans-
membrane part of human CD8
 
a
 
 and intracellular murine 
 
z
 
 was
 
made similar to that described in reference 28 by PCR using the
primers T7 and acim8z (5
 
9
 
-TCC TGC TGA ATT TTG CTC
TGT TGC AGT AAA GGG TGA TA-3
 
9
 
) and T3 and cim8z
(5
 
9
 
-TAT CAC CCT TTA CTG CAA CAG AGC AAA ATT
CAG CAG GA-3
 
9
 
). pcDNAZeo (Invitrogen Corp.) or the retro-
viral green fluorescent protein
 
 (
 
GFP)-RV (27) were used as plas-
mids. Tyrosines were replaced by phenylalanines using PCR as in
references 11 and 29. A stop codon was introduced after seven
amino acids of intracellular 
 
z
 
 with the primers 5
 
9
 
-TTC AGC
AGG AGT TAA GAG ACT GCT GCC-3
 
9
 
 and 5
 
9
 
-AAG TCG
TCC TCA ATT CTC TGA CGA CGG-3
 
9
 
.
 
Phosphotyrosine Blotting.
 
Transfected 3.L2 hybridoma cells (2 
 
3
 
10
 
7
 
) were incubated with 5 
 
m
 
g OKT-8 on ice and activated at
37
 
8
 
C for 5 min. Cells were lysed in 500 
 
m
 
l lysis buffer (17).
hCD8-
 
z
 
 was precipitated using OKT-8 and protein A–Sepharose
and analyzed by phosphotyrosine blotting using biotin–4G10
(Upstate Biotechnology Inc.) and horseradish peroxidase–strepta-
vidin (Southern Biotechnology Associates Inc.). The activation of
3.L2 T cell clones with peptide-pulsed Hi7 cells was previously
described (17). Phosphotyrosine bands were quantitated using
ImageQuant (version 1.1; Molecular Dynamics).
 
Results
 
TCR-
 
z
 
 Phosphorylation in the 3.L2 T Cell Clone.
 
The
TCR 
 
z
 
 chain is constitutively phosphorylated in resting pe-
ripheral T cells. To investigate constitutive as well as induced
TCR-
 
z
 
 phosphorylation, we first examined the 3.L2 T cell
clone. 3.L2 is specific for peptide Hb(64–76)/I-E
 
k
 
 (23). Pep-
tide Hb(64–76) is derived from an allelic form of murine he-
moglobin protein, amino acids 64–76. In rested 3.L2 T cells,
 
z
 
 was phosphorylated, as apparent in a phospho species of
21 kD termed p21 (Fig. 1 a). Stimulation of 3.L2 with fully
stimulating agonist peptide Hb(64–76) presented on APCs
augmented 
 
z
 
 phosphorylation and led to the appearance of
an additional phospho species of 23 kD called p23 (Fig. 1 a).
The 3.L2 TCR can also interact with a spectrum of peptide
ligands related to Hb(64–76) that have a one–amino acid
substitution at position 72 or 73 of the original protein se-
quence (23, 24). The response of the 3.L2 TCR to peptide
Hb(64–76) can be antagonized by such specific analogue
ligands (reference 24; Fig. 1 b). We used four analogue pep-
tide ligands of Hb(64–76), termed D73, I72, A72, and G72.
These peptides had the ability to inhibit proliferation of 3.L2
in a dose-dependent manner, as previously observed (refer-
ence 24; Fig. 1 b). This was a specific effect, as the control
peptide E72 did not inhibit proliferation, although it can
bind to I-E
 
k
 
 as well as peptides D73, I72, A72, and G72. Ex-
posure of 3.L2 to the four antagonist ligands D73, I72, A72,
and G72 also induced an increase in 
 
z
 
 phosphorylation (Fig.
1 a). However, more phosphorylation of p21 than p23 was
induced, resulting in a change in the ratio of p23/p21. This
type of 
 
z
 
 phosphorylation has previously been termed altered
 
z
 
 phosphorylation and is induced by many antagonist
ligands. Lastly, the control peptide E72 induced no augmen-
tation in 
 
z
 
 phosphorylation of the 3.L2 T cell (Fig. 1 a).
Antagonism of the 3.L2 T cell only occurs at certain
concentrations of agonist and antagonist ligands. For the
experiment shown in Fig. 1 b, the agonist Hb(64–76) was
used at the low but stimulating concentration of 10
 
2
 
7
 
 M. 
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At this dose, only very little 
 
z
 
 phosphorylation was induced
by Hb(64–76) (Fig. 1 a). Peptides G72, A72, I72, and D73
strongly induced antagonism when they were used at
higher concentrations of 10
 
2
 
5
 
–10
 
2
 
4
 
 M. At such concentra-
tions, the antagonist peptides induced very strong 
 
z
 
 phos-
phorylation (Fig. 1 a). Thus, at concentrations required for
antagonism, antagonist peptides induced more 
 
z
 
 phosphor-
ylation than the agonist peptide. This correlated with inhi-
bition of T cell activation rather than activation. In addition,
stronger antagonist peptides induced more 
 
z
 
 phosphoryla-
tion than weaker antagonist peptides at the same concen-
tration (Fig. 1 a, e.g., compare D73 and G72). Therefore,
the strength of the altered 
 
z
 
 phosphorylation signal corre-
lated with the strength of T cell inhibition.
We recently reported that the six tyrosines of the TCR 
 
z
 
chain are not phosphorylated to an equivalent degree (11).
Two main tyrosines, B1 and C2, are specifically phosphor-
ylated in resting T cells (Fig. 1 c). Upon activation with
fully stimulating ligands, A1 and A2 next become phosphor-
ylated. Tyrosines B2 and C1 are phosphorylated last, re-
sulting in the full phosphorylation of 
 
z
 
. In contrast, after
stimulation with antagonist ligands, only phosphorylation
of the basal sites B1 and C2 is markedly increased. A1 and
A2 are also inducibly phosphorylated, albeit only slightly.
The final phosphorylation of B2 and C1 is absent. Thus,
A1 and A2 phosphorylation is necessary but not sufficient
for the subsequent phosphorylation of C1 and B2, respec-
tively. In conclusion, the majority of phosphorylated 
 
z
 
molecules induced by antagonist ligands have only B1 and
C2 phosphorylated. These findings raise the question of
whether the distinct phosphorylated 
 
z
 
 species found in
resting T cells or after stimulation with either agonist or an-
tagonist ligands have an effect on T cell activation.
To directly test whether the partially phosphorylated
species found in T cells can inhibit T cell activation, we
substituted multiple tyrosines in 
 
z
 
 with phenylalanine to
prevent phosphorylation of these sites. This resulted in
proteins that could only be phosphorylated in the pattern
reflecting 
 
z
 
 phosphorylation as identified in T cells (11). In
particular, we designed mutants that allowed for the precise
Figure 1. TCR-z phosphorylation in the 3.L2 T cell clone. (a) TCR-z phos-
phorylation in the 3.L2 T cell clone. 107 3.L2 cells were stimulated with analogue
peptides E72, G72, A72, I72, and D73 or with the stimulatory peptide Hb(64–76)
and 2 3 106 APCs. Peptide concentrations were 1024 M for E72, G72, A72, I72,
and D73 and 1027, 1026, 1025, and 1024 M for Hb(64–76). Cells were lysed, the
TCR was precipitated using anti–Zap-70 antibodies, and tyrosine phosphoryla-
tion was examined by immunoblotting using 4G10 (PharMingen). The ratio of
p23/p21 at 1024 M was 0.75 for Hb(64–76), 0.55 for D73, 0.15 for I72, 0.11 for
A72, and 0.05 for G72. (b) The 3.L2 T cell can be antagonized with peptides
D73, I72, A72, and G72. B6.AKR splenocytes were prepulsed with 1027 M
Hb(64–76) peptide and washed. 3.L2 T cells were then added, as were increasing
doses of the analogue peptides D73, I72, A72, G72, and E72. 3.L2 T cells prolif-
erated in response to Hb(64–76) (dotted line). D73, I72, A72, and G72 antago-
nized proliferation in a dose-dependent manner, but the control peptide E72 did
not (solid lines). Data represent the mean of triplicate cultures with SD , 15% of
the mean. (c) Phosphorylation of z tyrosines A1–C2 proceeds in a specific order. In resting peripheral T cells, B1 and C2 are phosphorylated (left; d indicates
phosphorylation). Upon activation with agonist ligands, phosphorylation proceeds in the indicated order through an intermediate species (center) to full
phosphorylation (right). Antagonist ligands augment the phosphorylation of B1 and C2, whereas the subsequent steps are greatly diminished. (d) TCR-z was
mutated to only allow for phosphorylation found in resting T cells or phosphorylation after activation with antagonist or agonist ligands. Chimeric proteins
were prepared with the extracellular and transmembrane regions of human CD8a and the intracellular portion of murine z. F, tyrosine®phenylalanine sub-
stitution; d, unmodified tyrosines. The 4F mutant represents z found in resting T cells. After activation with antagonists, 4F is the predominant species,
whereas 3F and 2F are minor, intermediate forms. For the Stop mutant, a stop codon was introduced after seven amino acids of intracellular z.1630 Inhibition of T Cell Activation through the T Cell Receptor z Chain
phosphorylation found in resting T cells or phosphoryla-
tion induced by antagonist or agonist peptides (Fig. 1 d).
We designed these mutants as chimeric proteins with hCD8a
to provide a specific extracellular means for antibody cross-
linking and for quantifying expression (28).
The construct with four substitutions from tyrosine to phe-
nylalanine was termed 4F, and it retained only two intact
tyrosines for phosphorylation, B1 and C2 (Fig. 1 d). In
resting T cells, these two main tyrosines were found to be
phosphorylated with a high degree of specificity. In addi-
tion, stimulation with antagonist peptides led to a marked
augmentation of phosphorylation at B1 and C2 when com-
pared with resting T cells. Therefore, the 4F mutant not
only reflected the phosphorylation pattern of resting T cells
but also the main pattern induced by antagonist ligands.
The construct 3F, with three tyrosine mutations, reflected
an intermediate species. It allowed for the additional phos-
phorylation of tyrosine A2. A2 has been found to be phos-
phorylated to a minor degree in resting T cells. This was most
likely because phosphorylation of A2 varied depending on
the resting state of T cells (11). Phospho-A2 was also induced
by antagonist ligands. Thus, we could test a possible function
of A2, B1, and C2 phosphorylation with the 3F mutant.
The 2F mutant allowed the additional phosphorylation
of A1. One ITAM, ITAM A, could now be fully phosphor-
ylated, but B2 and C1 were mutated. A1 and A2 phosphor-
ylation is required for further phosphorylation of B2 and
C1. However, after stimulation with antagonist peptides,
A1 and A2 are found to be slightly phosphorylated without
the subsequent phosphorylation of B2 and C1. Thus, the
2F mutant represents a minor species present in antagonist-
activated cells but not in resting cells, and it was important
to test its function. 2F also reflects an intermediate species
in cells activated with agonist ligands, where A1 and A2 are
phosphorylated to an extensive degree before z then be-
comes fully phosphorylated.
Several control proteins were designed: a protein with-
out mutations in z, termed Wt, and two proteins with no
tyrosines available for phosphorylation, termed 6F and Stop.
4OF was another control that reflected a pattern of phos-
phorylation not found in T cell activation.
Partially Phosphorylated TCR-z Can Inhibit T Cell Activa-
tion of the 3.L2 T Cell Hybridoma. The mutants were trans-
fected into a hybridoma derived from the 3.L2 T cell.
Several clones for each construct were positive for surface
expression of hCD8a. Transfected 3.L2 cells with similar
hCD8-z expression levels were further analyzed (Fig. 2, a–g,
Figure 2. Expression of hCD8-z mutants in the murine 3.L2 T cell hy-
bridoma. (a–g) Left panels: the murine 3.L2 T cell hybridoma was trans-
fected with different hCD8-z mutants. Three to five independent transfec-
tants were identified for each construct by FACS® analysis using an antibody
to human CD8a, RPA-T8–PE (PharMingen). One representative subclone
for each mutant is shown. Right panels: TCR-mediated IL-2 production was
measured to demonstrate that the endogenous 3.L2 receptor is intact after the
transfection procedure. 2 3 104 Hi7 cells were incubated with 105 3.L2 cells
and increasing doses of the Hb(64–76) peptide. IL-2 was measured by growth
of the IL-2–dependent cell line CTLL. All transfected clones responded to
Hb(64–76)/I-Ek with similar sensitivity. The experiments were performed at
the same time as the experiments shown in Fig. 3 for each transfectant.
Dashed lines represent the amount of IL-2 production that resulted from ex-
posure to peptide-pulsed APCs in Fig. 3 for each experiment shown. Two
independent transfectants were analyzed with identical results for 6F, 4F, and
3F; one for Wt, Stop, and 2F; and three for 4OF. One transfectant for each
construct was then subcloned, and the experiments were performed nine
times. The data represent the mean of triplicate cultures with SD , 15% of
the mean.1631 Kersh et al.
through the Wt hCD8-z mutant alone (data not shown).
This indicated that unmutated intracellular z induced T cell
activation, consistent with previous observations (1–3). No
effect was observed when the 6F or Stop mutants were en-
gaged (Fig. 3, b and c), as tested in two independent clones
for 6F and one clone for Stop. Thus, the presence of the
hCD8-z molecule without tyrosines had no effect on T cell
activation. Interestingly, the IL-2 response to the TCR
ligand was inhibited when the 4F protein was cross-linked
in two independent clones (Fig. 3 d). Inhibition of the 3.L2
response was dose dependent, with 100% inhibition occur-
ring at the highest concentration of OKT-8. The 3F mu-
tant was also inhibitory in two independent transfectants (Fig.
3 e). Cross-linking of 2F augmented the IL-2 response in-
duced through the endogenous TCR (Fig. 3 f). It also in-
duced IL-2 production when cross-linked alone (data not
shown). Thus, this mutant had an activating effect on T cell
activation, consistent with previous studies of single intact
ITAMs (1). This indicated that the presence of one intact
ITAM in 2F overcame the inhibitory effect of tyrosines B1
and C2. The effect of all hCD8-z mutants was maximal when
TCR-mediated IL-2 production was intermediate and
within the linear portion of the dose–response curve. When
TCR-mediated stimulation was saturated, inhibition as
well as augmentation of IL-2 production was not notice-
able (data not shown). Thus, the concentration requirements
for stimulation were similar when inhibition was mediated
left panels). All tested transfectants retained their ability to
respond to the Hb(64–76)/I-Ek peptide in a dose-depen-
dent manner by IL-2 production (Fig. 2, a–g, right panels),
indicating that their endogenous 3.L2 receptor was intact
after the transfection procedure. Transfection with the dif-
ferent hCD8-z mutants did not significantly affect the sen-
sitivity of TCR-mediated IL-2 production for any of the
transfectant clones tested. We also determined an interme-
diate dose of Hb(64–76) that stimulated IL-2 production
within the linear part of the dose–response curve for each
transfectant (Fig. 2, a–g, right panels, dashed lines).
Next, we stimulated the transfected cell lines through
their endogenous 3.L2 TCRs with an intermediate dose of
Hb(64–76) peptide and APCs. This resulted in TCR-medi-
ated IL-2 production within the linear portion of the dose–
response curve (compare Fig. 2, a–g, right panels, dashed
lines and Fig. 3, a–g, dashed lines). At the same time, we
cross-linked the hCD8-z proteins by adding anti-hCD8a
antibodies and measured IL-2 production (Fig. 3, a–g, solid
lines). The experiments shown in Fig. 2, right panels, and
Fig. 3 were performed on the same day for each transfectant,
so the degree of peptide stimulation indicated with the dot-
ted lines in Fig. 3 can be directly compared with the dose–
response curve in Fig. 2.
Such treatment led to an augmentation of IL-2 produc-
tion in the Wt-transfected cell lines (Fig. 3 a). IL-2 produc-
tion was also induced when the cell line was stimulated
Figure 3. The hCD8-z mutants 3F, 4F,
and 4OF have an inhibitory effect on
TCR-mediated IL-2 production. Hi7 cells
were prepulsed with a stimulating dose of
Hb(64–76). 3.L2 cells were then incubated
with the prepulsed APCs alone (dashed
lines) or with prepulsed APCs and increas-
ing doses of anti-hCD8a antibody OKT-8
to cross-link the mutants (solid lines). 4F,
3F, and 4OF inhibited TCR-mediated IL-2
production (d, e, and g); Wt and 2F had an
augmenting effect on IL-2 production (a
and f), and 6F and Stop had no effect (b and
c). The peptide dose necessary for interme-
diate IL-2 production was determined for
each transfectant in previous experiments.
The peptide doses were 0.5 3 1026 M
Hb(64–76) for Wt, 6F, 3F, 2F, and 4OF;
1026 M for Stop; and 0.5 3 1027 M for 4F.
The experiments shown were performed at
the same time as the dose–response curves
shown in Fig. 2 for each transfectant. Two
independent transfectants were analyzed for
6F, 4F, and 3F; one for Wt, Stop, and 2F;
and three for 4OF with identical results.
One transfectant for each construct was
then subcloned, and the experiments were
performed nine times. The data represent
the mean of triplicate cultures with SD ,
15% of the mean.1632 Inhibition of T Cell Activation through the T Cell Receptor z Chain
by TCR antagonism and by hCD8-z mutants. In conclu-
sion, we identified two inhibitory z mutants, 4F and 3F.
These proteins contained two or three partially impaired
ITAMs and lacked intact ITAMs. Thus, we demonstrated
that the z species that represented phosphorylation in rest-
ing T cells can inhibit T cell activation. Such species are
also strongly induced by antagonist ligands.
Next, we tested whether the inhibitory effect was specif-
ically due to tyrosines B1 and C2 or whether the combina-
tion of other tyrosines could also inhibit T cell activation.
B1 and C2 were mutated to phenylalanine, as was ITAM
A. This left tyrosines B2 and C1 intact (Fig. 1 d, mutant
4OF). Three independent transfectants were examined.
The presence of hCD8-z 4OF did not alter the sensitivity
of the 3.L2 TCR (Fig. 2 g). Cross-linking of 4OF could
also inhibit TCR-mediated T cell activation (Fig. 3 g) in all
three clones. Inhibition was as efficient as with the 4F and
3F mutants. This indicated that the inhibitory effect was
not dependent on tyrosines B1 and C2. Rather, other
hemi-ITAMs could also inhibit T cell activation when in-
tact ITAMs were absent.
To test whether the inhibitory effect of z mutants was
also observed in other cell lines, we transfected 4F and 6F
into the 3A9 T cell hybridoma. 3A9 is specific for peptide
HEL(48–62)/I-Ak (25), a peptide derived from hen egg
lysozyme, amino acids 48–62. Two positive clones for each
construct were identified by expression of hCD8a, and
their responsiveness to HEL/I-Ak was confirmed (not
shown). Cross-linking of 4F but not 6F led to an inhibition
of TCR-induced IL-2 production in a dose-dependent
fashion (data not shown) in both independent clones tested
for each construct. Thus, the inhibitory effect of partially
phosphorylated z species was not limited to the 3.L2 T cell.
Inhibitory TCR-z Mutants Are Tyrosine Phosphorylated.
We next examined the tyrosine phosphorylation state of
the hCD8-z 6F, 4F, and Wt proteins in the transfected
3.L2 hybridoma lines. Untransfected 3.L2 or 3.L2 trans-
fected with 6F, 4F, or Wt was incubated with anti-hCD8a
antibodies and left on ice or antibody cross-linked (Fig. 4).
Cells were then lysed, the hCD8-z mutants were precipi-
tated, and tyrosine phosphorylation of the chimeric hCD8-z
protein was analyzed. In contrast to 6F, both 4F and Wt
were tyrosine phosphorylated. Interestingly, 4F and Wt
were both constitutively tyrosine phosphorylated to a simi-
lar extent before cross-linking of hCD8 (Fig. 4 a). This was
reminiscent of constitutive phosphorylation of z in resting
T cells. The electrophoretic mobilities of 4F and Wt dif-
fered from each other. This might be because point muta-
tions in z can affect its mobility significantly (11). Alterna-
tively, hCD8-z Wt could be phosphorylated to a higher
degree than 4F, giving rise to a lesser mobility. In this case,
the extent of phosphorylation of the hCD8-z Wt protein
in the hybridoma cell line might be higher than that of en-
dogenous TCR-z in resting nonimmortalized T cells. Phos-
phorylation of hCD8-z Wt significantly increased with ac-
tivation, whereas phosphorylation of 4F was unchanged.
This might be due to the binding of Zap-70 to fully phos-
phorylated ITAMs in hCD8-z Wt, which can protect ty-
rosines from dephosphorylation (30). Binding of Zap-70 to
phospho-4F might be impaired because no fully phosphor-
ylated ITAMs are present, resulting in the rapid dephos-
phorylation of phospho-4F. Alternatively, the effect of
cross-linking of the constitutively phosphorylated 4F mu-
tant might be exerted through aggregation or association
with the endogenous TCR and not through an increase in
phosphorylation. All transfected cell lines expressed hCD8-z
protein (Fig. 4 b). hCD8-z appeared as two separate bands in
immunoblotting, most likely due to glycosylation (28). In
conclusion, the remaining intact tyrosines in the inhibitory
mutant 4F were phosphorylated. As 6F had no effect on T
cell activation and was not phosphorylated, the inhibitory
effect of 4F was most likely exerted through phosphory-
lated tyrosines.
Partially Phosphorylated TCR-z Can Inhibit T Cell Prolifer-
ation. We next examined whether z mutants could also in-
hibit proliferation of nonimmortalized T cell lines. We used
T cells from 2.102 TCR–transgenic mice on a RAG-12/2
background (26). 2.102 T cells are specific for Hb(64–76)/
I-Ek but express a different a/b TCR than 3.L2. We trans-
duced such splenocytes by retroviral infection techniques
using a bicistronic retrovirus coexpressing hCD8-z mutants
and GFP (27). This enabled us to identify transfected T cells
by the expression of GFP without antibody cross-linking of
the hCD8a mutants. We infected activated 2.102 spleno-
cytes with retroviral supernatants containing empty vector or
hCD8-z Wt, 6F, and 3F on two independent occasions.
GFP-positive splenocytes were FACS® sorted, expanded, and
subcloned. Cells were then analyzed for the expression of
hCD8a and GFP by FACS® (Fig. 5, a–d, left panels). Cells
transduced with vector alone expressed GFP, indicating that
the infection procedure was successful. Cells transduced with
hCD8-z Wt, 6F, and 3F expressed both GFP and hCD8a.
All cell cultures responded to Hb(64–76)/I-Ek by prolifer-
ating with similar responsiveness, indicating that the en-
dogenous 2.102 receptor was still intact (data not shown).
We next examined the effect of the hCD8-z mutants. T
cells were either exposed to a stimulating dose of Hb(64–76)/
Figure 4. Inhibitory TCR-z
mutants are tyrosine phosphory-
lated. (a) hCD8-z mutants 4F
and Wt are tyrosine phosphory-
lated before and after cross-link-
ing of hCD8a. 2 3 107 untrans-
fected 3.L2 hybridoma cells or
3.L2 cells transfected with 6F,
4F, or Wt were incubated with
5 mg of anti-hCD8a OKT-8 on
ice. Samples were then activated
and cross-linked at 378C (1) or
left on ice (2). Cells were lysed, and the mutants were immunoprecipi-
tated using OKT-8 and analyzed by phosphotyrosine blotting using bio-
tin–4G10 (Upstate Biotechnology Inc.) and horseradish peroxidase–
streptavidin. The position of a 35-kD molecular mass marker is indicated
at left. (b) 3.L2 cells transfected with 6F, 4F, and Wt express hCD8-z
protein. An immunoblot was performed on the samples described in
panel a using 777, an antibody against murine z that also recognizes mu-
tant z (11). Two bands with different molecular sizes were apparent, most
likely due to glycosylation of the extracellular portion of hCD8a. Repre-
sentative of four experiments.1633 Kersh et al.
I-Ek alone (Fig. 5, a–d, right panels, dashed lines) or simul-
taneously exposed to Hb(64–76)/I-Ek and increasing doses
of anti-hCD8a (Fig. 5, a–d, right panels, solid lines). Such
treatment had no effect on the vector alone or 6F-transduced
cells (Fig. 5, a and c). Thus, neither the presence of anti-
hCD8a antibodies nor of extracellular hCD8a had an ef-
fect on T cell proliferation. Cross-linking of hCD8-z Wt
induced an increase in proliferation, indicating an activat-
ing effect (Fig. 5 b). When the 3F mutant was cross-linked,
proliferation to peptide-pulsed APCs was inhibited in a
dose-dependent manner (Fig. 5 d). This demonstrated that
partially phosphorylated z species could also inhibit T cell
activation in nonimmortalized T cells.
Discussion
Here we demonstrate that the type of TCR-z phosphor-
ylation present in resting T cells can inhibit T cell activa-
tion. Thus, the constitutive phosphorylation of the TCR
complex may not reflect a low level of ongoing T cell acti-
vation. Rather, it may serve to prevent any unintended T
cell activation. TCR-z phosphorylation induced by antag-
onist ligands can also inhibit T cell activation. Our analysis
therefore also supports the concept that TCR antagonism
can occur through the generation of an inhibitory signal
within the TCR complex.
Our findings raise questions about the mechanism of T
cell inhibition. We think that the inhibitory effect can be
exerted through the action of proteins that specifically bind
partially phosphorylated z. Such proteins could associate
with z through single SH2 domains or through other pro-
tein–protein interactions. During full T cell activation, the
stronger, cooperative binding of the tandem SH2 do-
mains of Zap-70 to doubly phosphorylated ITAMs might
displace these proteins. One possibility is that binding pro-
teins could be inhibitory phosphatases that are brought into
the vicinity of the endogenous TCR when inhibitory
hCD8-z mutants are antibody cross-linked. Alternatively,
binding proteins could be positively acting kinases present
in limiting amounts. Through their association with z, ki-
nases might become sequestered and then might no longer
be available to mediate T cell activation. A similar mecha-
nism has been identified for antagonist inhibition of the
high-affinity receptor for the Fc portion of IgE, FceRI
(31).
We overexpressed chimeric proteins and antibody cross-
linked their extracellular portion to study the role of par-
tially phosphorylated ITAMs. Similar approaches have been
widely used to establish the function and importance of in-
tact ITAMs and their signal amplification ability (1–3). In
such studies, a multitude of z ITAM mutants were exam-
ined for their potential to stimulate T cells (1, 2, 5–7). Here
we further extended the use of this experimental system
and expressed such chimeras in cells with functional endog-
enous TCRs of known specificity. This enabled us to study
the previously unaddressed question of whether mutant
ITAMs can also inhibit T cell activation. We used hCD8-z
chimeras because similar proteins with human intracellular
Figure 5. 3F can inhibit proliferation in 2.102 TCR-transgenic spleno-
cytes. (a–d) Left panels: expression of Wt, 6F, and 3F in 2.102 T cells.
hCD8-z mutants Wt, 6F, and 3F were cloned into a bicistronic retrovirus
coexpressing GFP. Retrovirus-containing supernatants were produced
using the packaging cell line Phoenix E in two independent infections. T
cells from the spleens of 2.102 TCR–transgenic, RAG-12/2 mice were
harvested, activated in vitro, and infected with retroviral supernatants
containing vector alone (a), Wt (b), 6F (c), or 3F (d). T cells were in-
fected on two separate occasions. GFP-positive cells were FACS® sorted,
restimulated, and subcloned. Two cell cultures for each construct were
then analyzed by FACS® for expression of GFP and hCD8a using RPA-
T8–PE (PharMingen). All cell cultures were positive for the expression of
GFP, and the Wt-, 6F-, and 3F-transduced T cells also expressed hCD8a.
Right panels: 3F can inhibit TCR-mediated proliferation. 3 3 104 2.102
T cells were stimulated with 5 3 104 CH27 cells prepulsed with Hb(64–
76). This led to T cell proliferation as measured with thymidine incorpo-
ration after 48 h (dashed lines). Alternatively, increasing doses of OKT-8
were added to the experiment to cross-link the hCD8 mutants (solid
lines). This led to an inhibition of T cell proliferation when 2.102 T cells
were transduced with 3F (d). OKT-8 had no effect on T cells transduced
with empty vector (a) or with 6F (c). The presence of Wt augmented
TCR-mediated proliferation (b). The Hb(64–76) doses necessary to ob-
tain intermediate levels of proliferation were determined in previous ex-
periments. Doses were 3 3 1026 M for vector alone, Wt, and 3F and
1026 M for 6F. The data represent the mean of triplicate cultures with
SD , 15% of the mean. The experiment was performed three times with
similar results.1634 Inhibition of T Cell Activation through the T Cell Receptor z Chain
z have been previously employed (1, 28). hCD8-z does not
associate with components of the endogenous TCR com-
plex before antibody cross-linking (28). It therefore does
not interfere with regulation of TCR signaling in the ab-
sence of cross-linking. In addition, the chimeric protein could
homodimerize, much like endogenous z.
Ardouin et al. (9) have recently published a report that T
cells from a P14 TCR–transgenic mouse lacking full z
ITAMs functioned normally. The mutant z, a1-,b1-,c1-, had
the amino terminal tyrosine of each ITAM converted to a
phenylalanine. These findings clearly showed that intact z
ITAMs are not needed for T cell development and func-
tion and that the four CD3 ITAMs are sufficient. In our
system, we did not examine the identical mutant, because
we have previously not found a TCR-z species phosphory-
lated simultaneously at tyrosines A2, B2, and C2 in T cells
(11). Our 3F mutant was the most similar but with differ-
ent tyrosines remaining. Based upon our findings, we would
have predicted that the a1-,b1-,c1- mutant would be inhibi-
tory; however, this was not observed. One possible expla-
nation was that only certain tyrosine residues were inhibi-
tory. Arguing against this is our result with the 4OF mutant.
An alternative explanation is that the remaining tyrosines in
the z molecule must be phosphorylated to be inhibitory.
Consistent with this, the a1-,b1-,c1- mutant was not found to
be phosphorylated, even upon pervanadate stimulation.
We studied the function of TCR-z, although TCR-z
ITAMs are not essential for T cell development and func-
tion, and CD3z2/2 mice reconstituted with z lacking all
three ITAMs appear largely normal. Clearly, the 10 TCR/
CD3 ITAMs have overlapping functions, but we contend
that their number and ordered phosphorylation collectively
provide the TCR with a mechanism by which it can dis-
criminate between closely related ligands. In the z ITAM-
less mice mentioned, the selection of T cells with specific
TCRs is altered, and autoreactive T cells can be found
(10). One difference between the components of the TCR
complex is that CD3e, CD3g, or CD3d is not constitu-
tively phosphorylated in resting peripheral T cells, whereas
CD3z is. T cells from mice expressing normal CD3e, CD3g,
and CD3d but mutated CD3z without ITAMs would there-
fore lack the inhibitory signal from partially phosphorylated
z. Thus, the autoreactivity found in such mice might not only
be due to altered thymic selection but also to increased pe-
ripheral reactivity.
To elucidate the mechanism of TCR antagonism, two
different known TCRs have recently been expressed on
the same T cell (32–34). “Cross-antagonism” of the two
TCRs would indicate that an inhibitory signal leads to TCR
antagonism. The outcome of the experiment varied, and
cross-antagonism was observed in some but not all cases.
This can be explained if TCR antagonism is induced by
differing mechanisms (35). Alternatively, depending on the
expression level and spatial separation of the two expressed
TCRs, a local inhibitory signal through one a/b TCR
may or may not affect signaling through a second TCR.
TCR antagonism can occur in the absence of functional
z (9, 36). We think that CD3e, CD3g, or CD3d can sub-
stitute for z ITAMs in the absence of z, as these proteins
can also substitute for z in T cell development. It remains
to be addressed whether CD3e, CD3g, or CD3d can be-
come partially phosphorylated after stimulation with antag-
onist ligands. CD3e was not phosphorylated after stimula-
tion with altered peptide ligands (17–19), but we recently
found that stimulation of the 3.L2 TCR with antagonist
ligands induces phosphorylation of CD3e (Kersh, E.N., and
P.M. Allen, unpublished results). Different cell lines might
therefore differ in their efficiency to induce CD3e phos-
phorylation, or certain antagonist ligands might be more
effective in inducing CD3e phosphorylation.
Our analysis of the 2F mutant provided insight into the
hierarchy of stimulatory versus inhibitory ITAMs. In the
2F mutant, functional ITAM A mediated T cell activation
despite the presence of inhibitory tyrosines B1 and C2.
This result was unanticipated, because in the 4F mutant, B1
and C2 alone had the ability to inhibit TCR-mediated IL-2
production. TCR-mediated IL-2 production is most likely
also the result of the phosphorylation of functional ITAMs
but within the TCR complex. However, the effect of such
phospho-ITAMs in the TCR complex could be inhibited
by the presence of B1 and C2 in the 4F mutant. We think
that the decision over activation or inhibition is made based
on a concentration difference of fully or partially phosphor-
ylated ITAMs: for inhibition, partially phosphorylated
ITAMs must far outnumber fully phosphorylated ITAMs. By
overexpression of 3F and 4F, fully phosphorylated ITAMs in
the endogenous TCR complex were outnumbered. How-
ever, in the 2F mutant, B1 and C2 could not outnumber
ITAM A, and therefore activation resulted.
In conclusion, we find that basal TCR-z phosphoryla-
tion in resting peripheral T cells inhibits T cell activation,
as do the subsequent first phosphorylation events and z
phosphorylation induced by antagonist ligands. These find-
ings add to our understanding of the complexity of signal
initiation at the TCR and strengthen our earlier interpreta-
tion that sequential z phosphorylation steps increase the fi-
delity of T cell activation (11).
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